Tesnatilimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTesnatilimab
Drug Alias NameNN-8555IPH-2301IPH-23XXJNJ-4500JNJ-64304500 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionNKG2-D type II integral membrane protein antagonists
TargetsNKG2-D type II integral membrane protein
Therapy Area/IndicationsInflammationAlopecia AreataCeliac Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesInnate Pharma
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc
Inactive CompaniesJohnson & Johnson (China) Investment LtdJanssen Pharmaceutical KkCilag Ag
Active IndicationsCrohn Disease
Inactive IndicationsInflammationAlopecia AreataCeliac Disease +[4] 

Other Information

ATC CodeN/A
Related LinksN/A